Matthias Schaefer

This inventor holds 19 USPTO granted patents and 2 published patent applications, plus 4 CIPO patents and 10 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Sanofi, Dow Technology Investments LLC. Active years: 2013-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matthias Schaefer. Retrieved from https://idiyas.com/inventor/matthias-schaefer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19 (Patent Applications = 2)

% Patents Active = 68.4

CIPO Patents = 4

EPO Patents = 10 (Patent Applications = 12)

Average Co-Inventor Count = 6.2

ph-index = 3

Forward Citations = 23(Granted Patents)

Location History:

Saxony, DE (2013)
Ehringshausen, DE (2013 - 2015)
Frankfurt-am-Main, DE (2013 - 2017)

Company Filing History:

Dow Technology Investments LLC

patents

Years Active: 2013-2017

Loading Chart...

Areas of Expertise:

Oxazolopyrimidine Derivatives

Carboxylic Acid Derivatives

Pharmaceuticals

Heterocyclic Compounds

Acylamino-Substituted Compounds

Fused Cyclopentanecarboxylic Acids

Acute Kidney Injury

Edg-1 Receptor Agonists

Cyclic Carboxylic Acids

Low Shear Gas Mixer

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9782411 - {4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury (2017-10-10),

2. 9328071 - Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals (2016-05-03),

3. 9321787 - Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring (2016-04-26),

4. 9040544 - 2,5-substituted oxazolopyrimidine derivatives (2015-05-26),

5. 9018383 - Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals (2015-04-28),

6. 8907093 - Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring (2014-12-09),

7. 8846692 - Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring (2014-09-30),

8. 8846691 - Heterocyclic carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring (2014-09-30),

9. 8846690 - Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring (2014-09-30),

10. 8802720 - Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals (2014-08-12),

11. 8785439 - 2,5,7-substituted oxazolopyrimidine derivatives (2014-07-22),

12. 8748436 - Carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring (2014-06-10),

13. 8735402 - Cycloalkyloxycarboxylic acid derivatives (2014-05-27),

14. 8735387 - Oxazolopyrimidines as Edg-1 receptor agonists (2014-05-27),

15. 8618304 - Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals (2013-12-31),

Title: The Innovative Mind of Matthias Schaefer: Revolutionizing Pharmaceutical Science

Introduction: Matthias Schaefer, a brilliant inventor based in Frankfurt am Main, Germany, has made significant contributions to the field of pharmaceuticals with his groundbreaking patents.

Latest Patents: Matthias Schaefer's latest patents showcase his expertise in developing cutting-edge pharmaceutical compounds. One of his remarkable inventions is the {4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid, designed for the prevention and treatment of acute kidney injury (AKI). Additionally, his work on acylamino-substituted fused cyclopentanecarboxylic acid derivatives demonstrates his commitment to creating valuable pharmaceutical active compounds for the treatment of various diseases.

Career Highlights: With a impressive portfolio of 18 patents, Matthias Schaefer has proven himself as a pioneering force in the pharmaceutical industry. Currently working at Sanofi, a leading pharmaceutical company, he continues to drive innovation and push the boundaries of pharmaceutical science.

Collaborations: In his journey towards innovation, Matthias Schaefer has collaborated with esteemed coworkers such as Dieter Kadereit and Thomas Huebschle. Together, they have worked tirelessly to develop novel pharmaceutical compounds and advance the field of medical science.

Conclusion: Matthias Schaefer's relentless pursuit of innovation and his invaluable contributions to the pharmaceutical industry underscore his status as a visionary inventor. His groundbreaking patents have the potential to revolutionize the treatment of various diseases, showcasing his unwavering dedication to improving healthcare outcomes globally.

Profile summary based on public USPTO records.